DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Chan A, Delaloge S, Holmes FA. et al.
ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol 2016;
17 (03) 367-377
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.